Verma S - Search Results

1

Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study.

Montvida O, Verma S, Shaw JE, Paul SK. Montvida O, et al. Among authors: verma s. Diabetes Obes Metab. 2020 Dec;22(12):2384-2397. doi: 10.1111/dom.14164. Epub 2020 Sep 10. Diabetes Obes Metab. 2020. PMID: 32744394

2

Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

Goldenberg RM, Verma S, Perkins BA, Gilbert JD, Zinman B. Goldenberg RM, et al. Among authors: verma s. Can J Diabetes. 2017 Feb;41(1):6-9. doi: 10.1016/j.jcjd.2016.08.001. Epub 2016 Nov 10. Can J Diabetes. 2017. PMID: 27838228 Review. No abstract available.

3

Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.

Goldenberg RM, Berall M, Chan CTM, Cherney DZI, Lovshin JA, McFarlane PA, Senior PA, Verma S, Weinstein JJ. Goldenberg RM, et al. Among authors: verma s. Can J Diabetes. 2018 Jun;42(3):325-334. doi: 10.1016/j.jcjd.2017.06.008. Epub 2017 Aug 16. Can J Diabetes. 2018. PMID: 28822777 Review.

4

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.

Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD; EMPEROR Trials Program. Butler J, et al. Among authors: verma s. Eur J Heart Fail. 2017 Nov;19(11):1390-1400. doi: 10.1002/ejhf.933. Epub 2017 Aug 24. Eur J Heart Fail. 2017. PMID: 28836359 Free article. Review.

5

SGLT2 inhibitors: practical considerations and recommendations for cardiologists.

Opingari E, Partridge ACR, Verma S, Bajaj HS. Opingari E, et al. Among authors: verma s. Curr Opin Cardiol. 2018 Nov;33(6):676-682. doi: 10.1097/HCO.0000000000000561. Curr Opin Cardiol. 2018. PMID: 30148719 Review.

6

Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?

Connelly KA, Bhatt DL, Verma S. Connelly KA, et al. Among authors: verma s. Cell Metab. 2018 Dec 4;28(6):813-815. doi: 10.1016/j.cmet.2018.11.010. Cell Metab. 2018. PMID: 30517896 Free article.

7

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials.

Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Verma S, et al. Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2. Diabetes Obes Metab. 2019. PMID: 30851070 Free PMC article.

8

Predictors of heart failure development in type 2 diabetes: a practical approach.

Verma S, Sharma A, Kanumilli N, Butler J. Verma S, et al. Curr Opin Cardiol. 2019 Sep;34(5):578-583. doi: 10.1097/HCO.0000000000000647. Curr Opin Cardiol. 2019. PMID: 31219877 Free PMC article. Review.

9

Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions.

Sharma A, Butler J, Zieroth S, Giannetti N, Verma S. Sharma A, et al. Among authors: verma s. Diabet Med. 2019 Dec;36(12):1550-1561. doi: 10.1111/dme.14140. Epub 2019 Oct 10. Diabet Med. 2019. PMID: 31536660 Review.

10

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.

Bhatt DL, Verma S, Braunwald E. Bhatt DL, et al. Among authors: verma s. Cell Metab. 2019 Nov 5;30(5):847-849. doi: 10.1016/j.cmet.2019.10.008. Cell Metab. 2019. PMID: 31693879 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,415 results

Search Page